MindCrowd Featured in the Phoenix Business Journal

“Before we can discover new treatments for brain-related diseases such as Alzheimer’s and Parkinson’s, we need to understand the human genetic blueprint – DNA – that determines how the brain works in healthy individuals,” he said. “Then we will be better equipped to develop new medicines and therapies for individuals with brain disorders.”

Matt Huentelman, PhD, Professor, Neurogenomics Division, Translational Genomics Research Institute (TGen)

In this profile in the Phoenix Business Journal, Dr. Matt Huentelman explains how crowdsourcing and his goal of reaching 1 million people may hold the keys to understanding the genetic underpinnings of Alzheimer’s disease and other brain-related disorders.

Visit the Phoenix Business Journal

And meet the TGen Alzheimer’s expert who wants to test 1 million people.

Read the full article.

One million people. One cause: MindCrowd.
One million people. One cause: MindCrowd.


MindCrowd is the first online research project of its kind to study millions of individuals to help bring us closer to a cure for Dementia.

Help us reach the 1 million people mark.

Stay Tuned for News about Brain Aging and How you Can Use them to Avoid Cognitive Decline.

You may opt out anytime. Privacy policy.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published.